Brief Report: Real-World Efficacy and Safety of Sotorasib in U.S. Veterans with KRAS G12C-Mutated NSCLC

Introduction: The KRAS G12C inhibitor sotorasib was approved for treating advanced NSCLC in the second line or later on the basis of the CodeBreaK100 trial. Nevertheless, data on the real-world efficacy and safety of sotorasib, and to its optimal dose, remain limited. Methods: Patients treated with...

Full description

Bibliographic Details

Published in:	JTO Clinical and Research Reports
Main Authors:	Katherine I. Zhou, MD, PhD, Chenyu Lin, MD, Chin-Lin Tseng, MPH, Nithya Ramnath, MBBS, Jonathan E. Dowell, MD, Michael J. Kelley, MD
Format:	Article
Language:	English
Published:	Elsevier 2024-05-01
Subjects:	Sotorasib KRAS KRAS G12C Non-small cell lung cancer (NSCLC) Real-world Dose reduction
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666364324000407